In the introduction to the last Bull Bear Market Report, I further developed the thesis that an impulsive equities bull market began in November 2012: Most analysts continue to make the mistake of believing that a secular bull market started in March of 2009. The actual situation of this market very closely parallels the 1974-1982 […]
The following companies might be the next big movers and winners of the 2011 year. With significant milestones achieved and unique products, they are leaders in their respective fields and are ready to deliver shareholder value in the coming months.
Bullish momentum looks to continue for VIVUS (NASDAQ:VIVUS) From a short-term perspective, as a daily trader it is easy to notice why Vivus has a lot of upside possibilities. A textbook Cup and Handle pattern is on the verge of forming (Dec.6.2010 – daily chart), where a breakout above $7.10 could lead to an easy […]
BullBear traders have been catching intermediate term swings in the stock market throughout 2010, including the bottom made a couple of days ago. With a few exceptions, particularly during the turbulent bottoming process from June-July, I’ve been consistently on the right side of the market. Here’s a peek inside the process which produced these results.
The S&P 500, SPDR (NYSE:SPY) has had an incredible run after gaining 3% in the past two days, especially given that is has been able to completely shrug off the negative fundamental data that has been pouring into the US markets. Expect the Financials Sector (NYSE:XLF) to take a haircut from recent gains, with Financials […]
Accentia is advancing a portfolio of potential blockbuster drug candidates which target multi-billion dollar market opportunities. These late-stage products include: BiovaxID®, a novel anti-idiotype cancer vaccine for the treatment of B-cell malignancies including indolent follicular non-Hodgkin’s lymphoma; Revimmune™, a novel ultra-high-dose formulation of a previously approved chemotherapeutic agent expected to show utility in the treatment of up to 80 autoimmune diseases, with an initial focus on multiple sclerosis; and SinuNase™, a novel formulation of a previously approved anti-fungal for the topical, intranasal treatment of chronic sinusitis.
Biovest International, Inc. is an emerging leader in the field of active personalized immunotherapies. In collaboration with the National Cancer Institute, Biovest has developed a patient-specific, cancer vaccine, BiovaxID®, with three clinical trials completed, including a Phase III study, demonstrating evidence of safety and efficacy for the treatment of indolent follicular non-Hodgkin’s lymphoma and mantle cell lymphoma. It is also developing an automated cell culture instrument. The company also sells hollow fiber bioreactors, cultureware, tubing sets, and other disposable products and supplies.
The US Dollar (NYSE:UUP) and (NYSE:UDN) has received nothing short of negative press since the introduction of Quantitative Easing part deux, amassing a total of $600 billion in printed paper (none of which is backed by gold bouillon). In theory, all exogenous variables equal, this event should depreciate the currency, however, it has done the […]
Next coming catalyst event for INVO Bioscience might come from Asia, with the expected Class II medical device classification for the INVOcell in China.
In August 10th, INVO Bioscience along with his distribution partner The Progressive Group, one of the larger med device and equipment distributors in this area, have started the registration process with Chinese FDA authorities.
“During the third quarter of 2010, our focus was on preparation of the 5 modules that make up the NDA submission for Marqibo(R)” stated Steven R. Deitcher, M.D., President and Chief Executive Officer of Hana Biosciences. “An analysis of data from the Menadione Topical Lotion Phase 1 program showed that it was generally safe and well tolerated. In addition, the dose limiting toxicity and apparent maximum tolerated lotion strength were identified. Our strategy is to seek a partner to enhance and accelerate the continued development of Menadione Topical Lotion.